Literature DB >> 25019963

8-Hydroxyquinoline Schiff-base compounds as antioxidants and modulators of copper-mediated Aβ peptide aggregation.

Luiza M F Gomes1, Rafael P Vieira1, Michael R Jones2, Michael C P Wang2, Christine Dyrager2, Elaine M Souza-Fagundes3, Jeferson G Da Silva4, Tim Storr5, Heloisa Beraldo6.   

Abstract

One of the hallmarks of Alzheimer's disease (AD) in the brain are amyloid-β (Aβ) plaques, and metal ions such as copper(II) and zinc(II) have been shown to play a role in the aggregation and toxicity of the Aβ peptide, the major constituent of these extracellular aggregates. Metal binding agents can promote the disaggregation of Aβ plaques, and have shown promise as AD therapeutics. Herein, we describe the syntheses and characterization of an acetohydrazone (8-H2QH), a thiosemicarbazone (8-H2QT), and a semicarbazone (8-H2QS) derived from 8-hydroxyquinoline. The three compounds are shown to be neutral at pH7.4, and are potent antioxidants as measured by a Trolox Equivalent Antioxidant Capacity (TEAC) assay. The ligands form complexes with Cu(II), 8-H2QT in a 1:1 metal:ligand ratio, and 8-H2QH and 8-H2QS in a 1:2 metal:ligand ratio. A preliminary aggregation inhibition assay using the Aβ1-40 peptide showed that 8-H2QS and 8-H2QH inhibit peptide aggregation in the presence of Cu(II). Native gel electrophoresis/Western blot and TEM images were obtained to give a more detailed picture of the extent and pathways of Aβ aggregation using the more neurotoxic Aβ1-42 in the presence and absence of Cu(II), 8-H2QH, 8-H2QS and the drug candidate PBT2. An increase in the formation of oligomeric species is evident in the presence of Cu(II). However, in the presence of ligands and Cu(II), the results match those for the peptide alone, suggesting that the ligands function by sequestering Cu(II) and limiting oligomer formation in this assay.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  8-Hydroxyquinoline; Alzheimer's disease; Copper(II) complex

Mesh:

Substances:

Year:  2014        PMID: 25019963     DOI: 10.1016/j.jinorgbio.2014.04.011

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  17 in total

1.  Inhibition of copper-mediated aggregation of human γD-crystallin by Schiff bases.

Authors:  Priyanka Chauhan; Sai Brinda Muralidharan; Anand Babu Velappan; Dhrubajyoti Datta; Sanjay Pratihar; Joy Debnath; Kalyan Sundar Ghosh
Journal:  J Biol Inorg Chem       Date:  2017-01-05       Impact factor: 3.358

2.  Aroylhydrazones constitute a promising class of 'metal-protein attenuating compounds' for the treatment of Alzheimer's disease: a proof-of-concept based on the study of the interactions between zinc(II) and pyridine-2-carboxaldehyde isonicotinoyl hydrazone.

Authors:  Daphne S Cukierman; Elio Accardo; Rosana Garrido Gomes; Anna De Falco; Marco C Miotto; Maria Clara Ramalho Freitas; Mauricio Lanznaster; Claudio O Fernández; Nicolás A Rey
Journal:  J Biol Inorg Chem       Date:  2018-08-25       Impact factor: 3.358

3.  Synthesis and antitumor mechanism of a new iron(iii) complex with 5,7-dichloro-2-methyl-8-quinolinol as ligands.

Authors:  Bi-Qun Zou; Qi-Pin Qin; Yu-Xia Bai; Qian-Qian Cao; Ye Zhang; Yan-Cheng Liu; Zhen-Feng Chen; Hong Liang
Journal:  Medchemcomm       Date:  2017-02-01       Impact factor: 3.597

4.  Synthesis, crystal structure, cytotoxicity and action mechanism of a Rh(iii) complex with 8-hydroxy-2-methylquinoline as a ligand.

Authors:  Yun-Liang Zhang; Qi-Pin Qin; Qian-Qian Cao; Hong-Hua Han; Zhu-Ling Liu; Yan-Cheng Liu; Hong Liang; Zhen-Feng Chen
Journal:  Medchemcomm       Date:  2016-10-25       Impact factor: 3.597

5.  Rational Design of a Cu Chelator That Mitigates Cu-Induced ROS Production by Amyloid Beta.

Authors:  Suchitra Mitra; Kallol Talukdar; Pallavi Prasad; Sandeep K Misra; Shabana Khan; Joshua S Sharp; Jonah W Jurss; Saumen Chakraborty
Journal:  Chembiochem       Date:  2021-12-30       Impact factor: 3.461

6.  Novel multifunctional iron chelators of the aroyl nicotinoyl hydrazone class that markedly enhance cellular NAD+ /NADH ratios.

Authors:  Zhixuan Wu; Duraippandi Palanimuthu; Nady Braidy; Nor Hawani Salikin; Suhelen Egan; Michael L H Huang; Des R Richardson
Journal:  Br J Pharmacol       Date:  2020-02-12       Impact factor: 8.739

Review 7.  Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease.

Authors:  Mercedes Unzeta; Gerard Esteban; Irene Bolea; Wieslawa A Fogel; Rona R Ramsay; Moussa B H Youdim; Keith F Tipton; José Marco-Contelles
Journal:  Front Neurosci       Date:  2016-05-25       Impact factor: 4.677

8.  ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy.

Authors:  José Marco-Contelles; Mercedes Unzeta; Irene Bolea; Gerard Esteban; Rona R Ramsay; Alejandro Romero; Ricard Martínez-Murillo; M Carmo Carreiras; Lhassane Ismaili
Journal:  Front Neurosci       Date:  2016-06-28       Impact factor: 4.677

9.  Multi-target-directed phenol-triazole ligands as therapeutic agents for Alzheimer's disease.

Authors:  Michael R Jones; Emilie Mathieu; Christine Dyrager; Simon Faissner; Zavier Vaillancourt; Kyle J Korshavn; Mi Hee Lim; Ayyalusamy Ramamoorthy; V Wee Yong; Shigeki Tsutsui; Peter K Stys; Tim Storr
Journal:  Chem Sci       Date:  2017-06-05       Impact factor: 9.825

10.  Synthesis and Cytoprotective Characterization of 8-Hydroxyquinoline Betti Products.

Authors:  Iván Kanizsai; Ramóna Madácsi; László Hackler; Márió Gyuris; Gábor J Szebeni; Orsolya Huzián; László G Puskás
Journal:  Molecules       Date:  2018-08-02       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.